Results 221 to 230 of about 558,941 (335)

Early Enoxaparin Treatment in a Newborn with Cerebral Venous Sinus Thrombosis and Acute Cerebellar Hemorrhage. [PDF]

open access: yesAJP Rep
Velardi M   +8 more
europepmc   +1 more source

Anti‐PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT‐like and VITT‐like characteristics

open access: yesBritish Journal of Haematology, Volume 206, Issue 6, Page 1737-1742, June 2025.
Summary Vaccine‐induced immune thrombocytopenia and thrombosis (VITT) is one of several anti‐platelet factor 4 (anti‐PF4)‐associated immune thrombocytopenia and thrombosis (PITT) syndromes. As well as following adenoviral vector vaccines, VITT has recently been described following acute adenovirus infection.
Phillip L. R. Nicolson   +17 more
wiley   +1 more source

Fulminant Idiopathic Intracranial Hypertension—Clinical Characteristics and Continuous Drainage as a Novel Treatment Approach

open access: yesEuropean Journal of Neurology, Volume 32, Issue 6, June 2025.
ABSTRACT Background Fulminant idiopathic intracranial hypertension (fIIH) is a severe condition which causes rapid visual loss. Conventional fIIH management involves surgical interventions, but their effectiveness and safety remain uncertain. The use of temporary continuous CSF drainage (CD) for fIIH has not been fully explored in the adult population.
Yoel Schwartzmann   +5 more
wiley   +1 more source

Abstracts

open access: yesMolecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Ten‐year follow‐up of a case of eosinophilic granulomatous with polyangiitis

open access: yes
ESC Heart Failure, Volume 12, Issue 3, Page 2361-2366, June 2025.
Jiange Qiao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy